Abstract

ASSESSING CIDOFOVIR EFFICACY IN THE TREATMENT OF EMERGING MONKEYPOX CASES

Samruddhi S. Kawalkar, Sakshi D. Chavhan*, Hrutwik M. Deshmukh, Narendra D. Umale and Dr. H. S. Sawarkar

.

Abstract

A broad-spectrum antiviral originally developed for treating CMV infections has shown potential for use against orthopoxviruses. Given the resurgence of monkeypox as a global health threat, the repurposing of existing antiviral agents like cidofovir is gaining attention. Monkeypox is related to the variola virus and can result in severe consequences. It is possible to reduce viral replication in studies involving orthopoxviruses with the use of cidofovir. There are promising results from pre-clinical studies on cidofovir’s effectiveness against monkeypox. It requires careful consideration of the side effect of the drug. There is a growing evidence that supports the utility of cidofovir in managing monkeypox. Further controlled trials are necessary to establish its efficacy and safety for broader clinical use against monkeypox. The current availability of newer antiviral drugs, such as tecovirimat, may influence treatment choices, but cidofovir remains a viable option in specific clinical scenarios, particularly where first-line treatments are unavailable or contraindicated. In conclusion, cidofovir holds promise as part of the therapeutic arsenal against monkeypox, especially for severe cases, though careful monitoring and more clinical trials are required to fully ascertain its role in the management of this emerging infectious disease.

Keywords: Monkeypox, Cidofovir, Antiviral, Smallpox